401 related articles for article (PubMed ID: 9172954)
1. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
[TBL] [Abstract][Full Text] [Related]
2. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
3. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
[TBL] [Abstract][Full Text] [Related]
6. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
Egbertson MS; Cook JJ; Bednar B; Prugh JD; Bednar RA; Gaul SL; Gould RJ; Hartman GD; Homnick CF; Holahan MA; Libby LA; Lynch JJ; Lynch RJ; Sitko GR; Stranieri MT; Vassallo LM
J Med Chem; 1999 Jul; 42(13):2409-21. PubMed ID: 10395482
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
10. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
Rübsamen K; Hornberger W; Kirchengast M
Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
[TBL] [Abstract][Full Text] [Related]
12. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs.
Furuya A; Nozawa M; Gotoh J; Jingu S; Akimoto M; Higuchi S; Suwa T; Ogata H
J Pharm Pharmacol; 2002 Jul; 54(7):921-7. PubMed ID: 12162710
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent stereopharmacokinetics of 5,6-dihydro-4H-4(isobutylamino)thieno(2,3-B)thiopyran-2-sulfonamide-7,7 -dioxide , a potent carbonic anhydrase inhibitor, in rats.
Lin JH; Ulm EH; Los LE
Drug Metab Dispos; 1991; 19(1):233-8. PubMed ID: 1673405
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in rabbits following single and multiple doses.
Lin JH; Chen IW; Ulm EH; Gehret JR; Duggan DE
Drug Metab Dispos; 1990; 18(6):836-41. PubMed ID: 1981525
[TBL] [Abstract][Full Text] [Related]
19. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
[TBL] [Abstract][Full Text] [Related]
20. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
Gilbert JC; DeFeo-Fraulini T; Hutabarat RM; Horvath CJ; Merlino PG; Marsh HN; Healy JM; Boufakhreddine S; Holohan TV; Schaub RG
Circulation; 2007 Dec; 116(23):2678-86. PubMed ID: 18025536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
